Last reviewed · How we verify
etanercept Treatment
Etanercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor that works by binding to TNF-alpha and preventing it from interacting with its receptors on cell surfaces.
Etanercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor that works by binding to TNF-alpha and preventing it from interacting with its receptors on cell surfaces. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | etanercept Treatment |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This action reduces inflammation and slows disease progression in conditions such as rheumatoid arthritis. Etanercept is a recombinant human TNF receptor fusion protein that acts as a decoy receptor for TNF-alpha, thereby inhibiting its pro-inflammatory effects.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Psoriatic arthritis
- Plaque psoriasis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Infection
- Nausea
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- Psoriasis Longitudinal Assessment and Registry
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
- TNF-α Treatment of Blast-Induced Tinnitus (PHASE2)
- Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis (PHASE3)
- Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- etanercept Treatment CI brief — competitive landscape report
- etanercept Treatment updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI